Ligand Pharmaceuticals (LGND) said Tuesday it expects 2025 core adjusted earnings of $6.00 to $6.25 per diluted share.
Analysts polled by FactSet expect $6.03.
The company said revenue for the year is expected to be between $180 million and $200 million.
Analysts surveyed by FactSet expect $183.1 million.
For 2024, the company said it continues to expect core adjusted earnings of between $5.50 and $5.70 on revenue of $160 million to $165 million. Analysts polled by FactSet expect core adjusted earnings of $5.65 on revenue of $163.4 million.
Price: 115.08, Change: -1.27, Percent Change: -1.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。